NCT06855095View on ClinicalTrials.gov

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

March 1, 2027

Conditions
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Neoplasm
Interventions
DRUG

Somatostatin analog

Timing of LA-SSA injection prior to PRRT (either 4-6 weeks or 1-7 days).

Trial Locations (1)

Unknown

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
collaborator

Neuroendocrine Tumor Research Foundation

UNKNOWN

lead

The Netherlands Cancer Institute

OTHER